Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short term Debt: 2020-2021

Historic Short term Debt for Tg Therapeutics (TGTX) over the last 2 years, with Dec 2021 value amounting to $975,000.

  • Tg Therapeutics' Short term Debt fell 95.60% to $975,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $975,000, marking a year-over-year decrease of 95.60%. This contributed to the annual value of $975,000 for FY2021, which is 95.60% down from last year.
  • Tg Therapeutics' Short term Debt amounted to $975,000 in FY2021, which was down 95.60% from $22.2 million recorded in FY2020.
  • Tg Therapeutics' 5-year Short term Debt high stood at $22.2 million for FY2020, and its period low was $975,000 during FY2021.
  • For the 2-year period, Tg Therapeutics' Short term Debt averaged around $11.6 million, with its median value being $11.6 million (2020).
  • Data for Tg Therapeutics' Short term Debt shows a maximum YoY tumbled of 95.60% (in 2021) over the last 5 years.
  • Over the past 2 years, Tg Therapeutics' Short term Debt (Yearly) stood at $22.2 million in 2020, then slumped by 95.60% to $975,000 in 2021.